As Applied Genetic Technologies Corp. takes the next steps in the development of its lead gene therapy candidate for inherited retinal disease, the company has…Read More
SAN FRANCISCO – Advances in glaucoma genetics potentially hold the key to new therapies for prevention, early detection, and a cure, researcher Janey L. Wiggs,…Read More
Since announcing disappointing clinical trial results for one of its lead ophthalmic gene therapy candidates and the termination of its collaboration agreement with Biogen, Applied…Read More
The first human gene therapy trial started in 1990, and over the course of that decade a multitude of questions about the safety and efficacy…Read More
The first Ophthalmology Innovation Awards were presented last night at the OIS-X Gala. Here’s a rundown of the award winners. Clinical Innovator: Ike Ahmed, MD…Read More
Major pharma companies in ophthalmology aren’t the only ones making plays in the gene therapy space, as we reported last week. Mid-size and small companies…Read More
When Allergan and Editas Medicine disclosed this week that they would move forward on their collaboration to develop a genome editing-medicine for treatment of an…Read More
Eye care commanded a key stage at the 21st Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) last week in Chicago.…Read More
Here are 15 takeaways from last week’s OIS@ASCRS 2018. Barry Cheskin of PowerVision reported on a pilot study of 27 patients who had the FluidVision…Read More
There are 41 different sessions, panels, and presentations happening at OIS@ASCRS 2018 – including five different breakout sessions on everything from dry eye to emerging…Read More
An emerging gene therapy candidate for the treatment of inherited eye disease has taken a step forward with MeiraGTx announcing that it has received Priority…Read More
The race to find an effective treatment for geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD) for which no approved treatment exists,…Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.